Legal Cannabis Higher Potency & Higher Risks

Victor L. Vines, MD, ABPM Midwest Regional Medical Director Hazelden Betty Ford Foundation




Dr. Victor Vines

Midwest Regional Medical Director Hazelden Betty Ford Foundation



Cannabis Sativa—Marijuana







Legal Cannabis Higher Potency & Higher Risks

Objectives

- Examine data on increased mental and physical health disorders in states with legalized cannabis
- Review what's known (and not known) about the cannabis plant and its derivatives
- Discuss the dose-response relationship between THC concentration and health consequences
- Identify likely issues and scenarios for health care providers given increased availability and strength of cannabis products




History of Marijuana

- 1378 Soudoun Sheikouni, the Emir of the Ottoman Empire outlawed use of hashish and cannabis across his jurisdiction. Sheikouni's prohibition is one of the earliest, if not the earliest, attested cannabis ban in the world, the first "War on Drugs"
- 1798 Following Napoleon's invasion of Egypt, concerned by his troops' use of hashish and cannabis-based beverages, he banned the drug and the establishments that provided it.
- 1868 Egypt 1st modern country to outlaw cannabis ingestion
- 1890 Hashish made illegal in Turkey



Hashish—Hash, Charas, Norwegian Wood







History of Marijuana

- Introduced to North America in 1600s by Puritans Hemp for ropes, sails, clothing; cannabis a common ingredient in medicines, sold openly in pharmacies
- 1937 Marijuana Tax Act (MTA) transfer of cannabis illegal throughout US except for medicinal and industrial use, expensive excise tax and detailed logs required
- 1969 MTA found to be unconstitutional since it violated 5th Amendment privilege against self-recrimination



History of Marijuana


- 1969 Nixon formally declared a "War on Drugs" that would be directed toward eradication, interdiction, and incarceration
- 1970 Controlled Substance Act classified cannabis as having <u>high abuse potential, no medical use, not safe</u> to use under medical supervision
- 1986 Dronabinol placed into Schedule II by DEA
- 2003 Canada 1st country in world to offer medical marijuana to patients



Cannabis Sativa—Marijuana










Sinsemilla

Spanish term from sin (without) + semilla (seed)







Cannabis Sativa—Marijuana

- Complex alkaloid mixture of more than 400 compounds derived from the Cannabis sativa plant
- 84 different compounds described with activity on the cannabinergic system
- Most abundant cannabinoids are
 - Delta-9 tetrahydrocannabinol (most psychoactive)
 - Cannabidiol (CBD)
 - Cannabinol





Cannabis Indica—Hemp




Delta-8 Tetrahydrocannabinol




Cannabinergic System

- Two main cannabinoid receptors
- CB1—present throughout CNS
 - Hippocampus
 - Cortex
 - Olfactory areas
 - Basal ganglia
 - Cerebellum
 - Spinal cord
- CB2 located peripherally,
 linked with immune system
 - Spleen
 - macrophages

THC molecules are 'imposters'







Cannabinergic System

- Endocannabinoid system responsible for:
 - Neuronal communication
 - Plasticity
 - Learning
 - THC
 - Overwhelms endocannabinoid processing
 - Disrupts information processing
 - Impairs memory



Synthetic Cannabinoids

- Synthetic cannabinoids are FULL agonists at CB1 receptor
 - Stronger than Sinsemilla cannabis
- (THC and natural cannabinoids are partial agonists)
- Synthetic cannabinoids not detectable on routine UDS
- Familiar street names:
 - K2
 - Spice
 - Kush
 - Blaze
 - RedX Dawn
 - Black Magic




Synthetic Cannabinoids

- Psychosis with synthetics:
 - Catatonic posturing
 - Bizarre behavior
 - Grandiosity
 - Persecutory ideation
 - Disinhibition
 - Aggression
- Tachycardia, palpitations, chest pain
- May overwhelm stabilizing effect of anti-psychotics, even with parenteral administration



High CB1 Cannabinoid Receptor Density



NIDA website. Marijuana/effects. 2020.


Times Have Changed: 2007

Medical Marijuana in the USA

Eleven Years of Marijuana Reform & Compassion ©2007 Oregon NORML www.ornorml.org

Medical Marijuana is Accepted Considering Medical Marijuana

Medical Marijuana is Rejected Special Circumstances





FOR Easing Cannabis Regulations:

2019 Forbes Survey

- Cannabis has medicinal benefits
- Law enforcement could focus more on other crimes
- Individual freedom and choice
- Potential tax revenue
- Regulation would make it safer
- Don't believe marijuana is harmful



AGAINST Easing Cannabis Regulations:

2019 Forbes Survey

- Increased car accidents due to impaired driving
- Marijuana is a gateway to harder drugs
- More people would use marijuana
- Legalization wouldn't benefit society or people
- Believe that marijuana is harmful
- Believe that drug use is immoral




Times are changing...

- Vox.com
- Election Day was a major rejection of the war on drugs
 - In every state where marijuana legalization or another drug policy reform was on the ballot, it won.
- By German Lopez
 - @germanrlopez
 - german.lopez@vox.com
 - Nov 4, 2020, 9:30am EST




Times Have Changed—2021

Marijuana laws in the US





And It's Not Red Vs. Blue





From popular media:

 A handful of other states across the country that have already legalized and decriminalized the drug for recreational and medical use, suggesting that voters have changed their minds about whether marijuana is a gateway drug and whether people deserve to go to jail for possessing it.

• Fatherly.com 2/23/2021



Marijuana Legalization

Recreational and "Medicinal" use

- Adults 21 and older
- May legally possess and use
- May legally purchase (eventually)
- Home growing allowed (for some states)
- Penalties for illicit production, distribution and importation will remain

- State agencies will regulate
 - Production
 - Distribution
 - Sales
 - Taxation
- Local jurisdictions may be able to ban marijuana retailers within their borders



Marijuana Decriminalization

Not the Same as Legalization

- Reflects changing social and moral views about cannabis
- Does not allow for sale of cannabis
- Removes criminal penalties for possession or use
 - No criminal prosecution
 - No incarceration

- Implementation of fines and civil penalties
- Often coincides with contingencies:
 - Referral for clinical assessment
 - Educational activities
 - Requirement for treatment of addiction
- Penalties for illicit production, distribution and importation will remain (similar to legalization)



FDA- Approved Cannabinoids Are Already Available in U.S.

- Dronabinol (Marinol®) = (Synthetic Δ9-THC);
 - Schedule III, approved for CINV, wasting syndrome in AIDS
- Nabilone (Cesamet®) = (Synthetic cannabinoid)
 - Schedule II, approved for CINV
- Nabiximols (Sativex®) = (1:1 CBD/THC)
 - oral mucosal spray, not approved in U.S., used in Canada and Europe. Currently in Phase III trials in US for MS, cancer pain, CINV



Marijuana and Addiction

- Approximately 8-10% of regular marijuana users develop dependence.
- 17% develop dependence if use begins as teenager
- 25-50% of daily smokers develop dependence/addiction
- Compared with
 - 15% alcohol
 - 26% opiates
 - 32% nicotine



High THC / Low CBD and Psychosis

- Frequency of use: Cannabis Use Psychosis
 - Daily high psychosis association, especially w/ high potency THC
 - Non-daily variable psychosis association, not related to potency
 - < Weekly no psychosis association, regardless of potency
- Genetic risk of psychosis: Cannabis Use Psychosis
- Bidirectional relationship most likely: Cannabis Use Psychosis
- Next priorities:
 - Determine who is at risk from daily potent use
 - Address identified at risk with
 - Educational strategies
 - Mitigation efforts



Cannabis Use Disorder DSM-5 Criteria


DSM-5 Criteria for CUD

A. Problematic pattern of cannabis use leading to clinically significant impairment or distress

B. ≥ 2 of the following occurring over a 12-month period

- 1. Cannabis often taken in larger amounts or over a longer period of time than was intended
- 2. Persistent desire or unsuccessful effort to cut down or control cannabis use
- 3. Great deal of time spent in activities necessary to obtain cannabis, use cannabis, or recover from its effects
- 4. Recurrent use resulting in failure to fulfill major role obligations at work, school, or home
- 5. Continued use despite persistent or recurrent social or interpersonal problems caused or exacerbated by its effects
- 6. Important social, occupational, or recreational activities given up or reduced because of cannabis use
- 7. Recurrent cannabis use in situations in which it is physically hazardous (eg, driving or operating machinery)
- 8. Continued use despite persistent or recurring physical or psychological problem caused or exacerbated by its effects
- 9. Tolerance
- 10. Withdrawal
- 11. Craving or strong desire to use

High CB1 Cannabinoid Receptor Density



Health and Safety—Cannabis and Driving

Cannabis Effects on Driving Occasional Users in a Driving Simulator



 Increased variability in speed

 Increased variability in vehicle gap maintenance



- Increased Standard
 Deviation of Lateral
 Placement, a measure of weaving
- Reduced speed relative to speed limit


Duration of impairment after consumption (smoking): 4 to 6 hours

Hartman RL, et al. Clin Chem. 2013;59:478-492; Hartman RL, et al. Drug Alcohol Depend. 2015;154:25-37; Hartman RL, et al. J Appl Toxicol. 2016;36:1418-1429.



Health and Safety—Cannabis and Driving


Cannabis Effects on Driving Iowa/NIDA Driving Simulator Study



Hartman RL, et al. Drug Alcohol Depend. 2015;154:25-37.



Cannabis and Rx Opioid Use Disorder





Cannabis and Opioid Use Disorder

- Majority of individuals who misuse Rx pain meds and/or heroin initiate drug use early teens
 - Alcohol
 - Marijuana
- Biologically primes brain for enhanced response to other drugs later in life

- Journal of Addiction Medicine (2018)
 - Nationally representative data
 - Medical marijuana users have twice the risk for prescription opioid misuse compared to nonusers of medical marijuana



Cannabis and Opioid Overdose Mortality

- M. A. Bachhuber, B. Saloner, C. O. Cunningham, C. L. Barry, <u>Medical cannabis laws and opioid analgesic overdose mortality in the United States</u>, 1999-2010. JAMA Intern. Med. 174, 1668–1673 (2014).
- Association between medical cannabis laws and opioid overdose mortality has reversed over time. Chelsea L. Shover, Corey
 Davis, Sanford Gordon, Keith Humphreys Proceedings of the National Academy of Sciences Jun 2019, 116 (26) 12624-12626; DOI: 10.1073/pnas.1903434116
- https://www.pnas.org/content/116/26/12624?blm_aid=29695



What Is the Evidence for Cannabis as a Medication?

- Nausea and vomiting in cancer chemotherapy (CINV)
 - 2010 Cochran review- "probably effective" in children but with high incidence of side effects; inadequate evidence for effectiveness in adults
 - European meta-analysis of synthetic cannabinoids showed superior anti-emetic effects but higher side effects
 - Additional concern- cannabis induced hyperemesis
- Glaucoma- probably not effective in reasonable doses
- Wasting syndrome in AIDS- inadequate evidence, studies flawed
- Muscle spasms, spasticity- variable results with MS, small studies
- Insomnia- small study showed improvement in sleep patterns in fibromyalgia patients
- Pain- reviews show some benefits but studies are hard to compare



What Are Risks, Adverse Effects

- Side effects
- Addiction
- Impaired motor skills
- Cognitive impairment
- Motivational impairment
- Risks associated with method of consumption
- Special risks for adolescents
 - Impact on brain development
 - Psychotic syndromes
- Cyclic vomiting syndrome
- Accidental ingestion by children or household pets



Liability Concerns for Providers

- <u>Duty of care</u>: Does recommending marijuana constitute a traditional provider-patient relationship?
- Breach of duty: Does recommending marijuana, despite lack of high-quality evidence for its efficacy constitute a breach of duty?
- Causation: Was patient harmed by exposure to recommended marijuana?
- No documented malpractice cases. Yet.
- Be wary of recommending/certifying marijuana for mental health or medical issues for which high-quality evidence does not exist.



References

Cannabis and psychosis: triangulating the evidence. Lancet Psychiatry, online 3/29/2019

Cannabinoid receptors: where they are and what they do. Journal of Neuroendocrinology, 20 (S1)

Novel psychoactive substances: identifying and managing acute and chronic harmful use. BMJ, Jan 25, 2017

Clearing Away the Confusion: Marijuana is not a Public Health Solution to the Addiction Crisis. Hazelden Betty Ford Foundation, Emerging Drug Trends Report, July 2019

Mental health-related emergency department visits associated with cannabis in Colorado. Academic Emergency Medicine, Vol 25 (5), May 2018

Public Policy Statement on Marijuana, Cannabinoids, and Legalization. American Society of Addiction Medicine, 2015

Cannabis use and risk of prescription opioid use disorder in the United States. American Journal of Psychiatry, 175(1), 47-53.

Election Day was a major rejection of the war on drugs. https://www.vox.com/2020-presidential-election/2020/11/4/21548800/election-results-marijuana-legalization-drug-decriminalization-new-jersey-arizona-oregon-montana

The Arguments for and Against Marijuana Legalization in The U.S. https://www.forbes.com/sites/niallmccarthy/2019/06/14/the-arguments-for-and-against-marijuana-legalization-in-the-u-s-infographic/?sh=7a8c148c678b

Medical marijuana users are more likely to use prescription drugs medically and nonmedically. Journal of Addiction Medicine, 2018 12(4), 295-299

Talking to Your Patients About Cannabis and Driving Safety (Medscape CME 0.5 credits) https://www.medscape.org/viewarticle/938043 slide

Medical Marijuana; Liability Issues for Mental Health Providers. Journal of Addictions Nursing, 2021. Vol 32, No 1, 73-76







This document is intended for individual use and educational purposes only and is not a substitute for professional advice or services. Please consult your doctor or other medical professional before modifying, changing or embarking on any new course of treatment or conduct. The views expressed herein are those of the presenter only; they do not necessarily reflect the view of the Hazelden Betty Ford Foundation. © 2020 Hazelden Betty Ford Foundation. All rights reserved. Images page 1, 14 and 24, multi-seat iStock.

Cigna Behavioral Health Awareness

If you are a Cigna customer and have questions about Substance Use treatment or about your benefits and how to use them, please contact:

Stephanie Gissal - 800.274.7603 x398516 Alex Turner - 800.274.7603 x513597 Wanda Russell – 800.274.7603 x342063